Immune cell subset is associated with development of gastrointestinal GVHD after HSCT

Gastrointestinal graft vs. host disease (GI-GVHD) is a life threatening complication that can occur after allogeneic hematopoietic cell transplantation, a procedure that is commonly used to treat patients with leukemia. There is currently no way to predict which patients will develop GI-GVHD before the presentation of clinical symptoms. Unfortunately, the symptoms of GI-GVHD are not very specific and many patients undergo treatment for GI-GVHD in the absence of a confirmed diagnosis because the disease is so dangerous.

In this issue of JCI Insight, researchers led by Sophie Paczesny of Indiana University School of Medicine report the identification of a subset of that express the protein CD146 and are increased in that went on to develop GI-GVHD prior to the onset of clinical symptoms.

Paczesny and colleagues demonstrated that mice lacking CD146-expressing T cells had improved survival following allogeneic hematopoietic cell transplantation.

These findings indicate that the CD146-expressing cell subset could potentially be used as a marker to identify patients who are likely to develop GI-GVHD after .

Explore further

Donor epstein-barr serostatus influences GVHD after allo-HSCT

More information: Wei Li et al, Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease, JCI Insight (2016). DOI: 10.1172/jci.insight.86660
Citation: Immune cell subset is associated with development of gastrointestinal GVHD after HSCT (2016, May 5) retrieved 29 July 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments